Rome, May 6 (beraking latest news Health) – A single booster dose of the Moderna vaccine “increased neutralizing titers against Sars-CoV-2 and against two variants of concern (South African and Brazilian) in participants in previously vaccinated clinical trials.” The company Moderna announced in a note, reporting the first results of an ongoing clinical study, in which it is testing a 50 microgram booster dose in individuals already vaccinated. Preliminary data show that this dose increased neutralizing antibody responses against the original virus, as well as against variants identified in South Africa and Brazil, and booster doses were ‘generally well tolerated’.
“As we seek to defeat the ongoing pandemic, we remain proactively committed to following the evolution of the virus. We are encouraged by this new data, which bolsters our confidence that our recall strategy can be protective against these newly identified variants.” , explained Stéphane Bancel, CEO of Moderna. “The strong and rapid push of titers to levels above primary vaccination also clearly demonstrates mRna-1273’s ability to induce immune memory – he continued – Our mRna platform enables rapid design of vaccine candidates incorporating key virus mutations. potentially allowing for a more rapid development of future alternative vaccines coupled with the variants, should they be needed. ”
“We look forward to sharing data on our multivalent booster candidate, mRna-1273.211, which combines mRna-1273 and mRna-1273.351 into a single vaccine, when available. We will continue to make any necessary updates to our Covid-19 vaccine to check the pandemic “, concluded Bancel.
COPYRIGHT today © breaking latest news